ERBB2 and bone metastasis: Previous articles showed that TNBC had a significantly lower rate of bone metastasis than HR+/HER2- tumors 18, and that HR-/HER2+ patients had a higher risk of brain metastasis than HR+/HER2- patients 19, 20.